Plain-English translation of NCT06249438 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called C-CAR168, which is a type of cell therapy created from your own immune cells. The researchers will remove some of your T cells (a type of white blood cell), modify them in the laboratory to recognize and fight the cells causing your autoimmune disease, and then give them back to you through an IV infusion. The goal is to help people whose autoimmune diseases have not improved despite trying standard medicines.
Many people with serious autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis don't get better with the usual treatments available today. This medication represents a completely new approach—using your own immune cells as a 'living medicine' to control the disease at its source—offering hope for patients who have few other options.
You likely qualify if…
You likely don't qualify if…
If you join this study, doctors will first collect some of your T cells through a procedure similar to a blood draw or apheresis (a machine that separates out specific cells). These cells will be sent to a laboratory where they are modified and grown over several weeks. Once ready, you will receive the modified cells back as an IV infusion in the hospital. You will then be monitored closely with blood tests and clinic visits to watch for any side effects and to see whether the treatment is helping your disease.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China